ImpediMed Limited
ImpediMed Limited (IPD.AX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for ImpediMed Limited (IPD.AX), featuring income statements, balance sheets, and cash flow data.
ImpediMed Limited (IPD.AX) Income Statement & Financial Overview
Review ImpediMed Limited IPD.AX income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $6.008M | $5.54M | $4.78M | $5.69M |
| Cost of Revenue | $717000.00 | $682000.00 | $12.61M | $12.10M |
| Gross Profit | $5.29M | $4.85M | -$7.83M | -$6.41M |
| Gross Profit Ratio | $0.88 | $0.88 | -$1.64 | -$1.13 |
| R&D Expenses | $0.00 | $1.77M | $125000.00 | $111000.00 |
| SG&A Expenses | $14.03M | $11.73M | $4.13M | $3.95M |
| Operating Expenses | $16.87M | -$5.68M | $4.26M | $4.06M |
| Total Costs & Expenses | $17.59M | -$5.00M | $16.87M | $16.16M |
| Interest Income | $0.00 | $676000.00 | $883000.00 | $475000.00 |
| Interest Expense | $0.00 | $44000.00 | $49000.00 | $29000.00 |
| Depreciation & Amortization | $2.21M | -$582000.00 | $1.16M | $1.31M |
| EBITDA | -$9.37M | -$11.70M | -$11.75M | -$9.16M |
| EBITDA Ratio | -$1.56 | -$2.11 | -$2.46 | -$1.61 |
| Operating Income | -$11.58M | $10.53M | -$12.09M | -$10.47M |
| Operating Income Ratio | -$1.93 | $1.90 | -$2.53 | -$1.84 |
| Other Income/Expenses (Net) | $442000.00 | -$20.59M | $1.85M | $270000.00 |
| Income Before Tax | -$11.13M | -$10.06M | -$10.24M | -$10.20M |
| Income Before Tax Ratio | -$1.85 | -$1.82 | -$2.14 | -$1.79 |
| Income Tax Expense | $11000.00 | $13000.00 | -$518000.00 | -$496000.00 |
| Net Income | -$11.15M | -$10.07M | -$9.72M | -$9.71M |
| Net Income Ratio | -$1.86 | -$1.82 | -$2.03 | -$1.71 |
| EPS | -$0.005 | -$0.005 | -$0.005 | -$0.005 |
| Diluted EPS | -$0.005 | -$0.005 | -$0.005 | -$0.005 |
| Weighted Avg Shares Outstanding | $2.23B | $2.05B | $2.43B | $1.82B |
| Weighted Avg Shares Outstanding (Diluted) | $2.23B | $2.05B | $2.43B | $1.82B |
Over the last four quarters, ImpediMed Limited's revenue moved from $5.69M in Q4 2023 to $6.008M in Q2 2025. Operating income in Q2 2025 was -$11.58M, with a strong operating margin of -193%. Despite fluctuations in R&D and SG&A expenses, EBITDA for ImpediMed Limited remained robust at -$9.37M, reflecting operational efficiency. Net income dropped to -$11.15M, with an EPS of -$0.005. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan